← Leaderboards
Jianjun Zhang
University Of Tx Md Anderson Can Ctr
$2,808,388
Attributed
$4,779,803
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $987K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,779,803 · 2
By mechanism
U01$2,957,123 · 1
R01$1,822,680 · 1
Top collaborators
- Lauren Averett Byers5 shared
- John V. Heymach5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Eduardo Vilar Sanchez$16,310,319
- Lauren Averett Byers$9,117,683
- Scott Kopetz$13,199,822
- Ronald Anthony Depinho$97,148,322
- Don Lynn Gibbons$4,258,623
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularHeterogeneityMalignant NeoplasmsMinimally InvasiveImmuneMouse ModelGenomicsImmunotherapyResectedSamplingT-LymphocyteTumorPreventBioinformaticsClinical TrialsEvolutionBiological MarkersTumor ProgressionRelapseBaseAdenocarcinoma In SituAscl1 GeneCell LineCancer Subtypes
Grant awards (10)
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$605,520
U01 · FY2025 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$575,245
U01 · FY2024 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$561,956
U01 · FY2023 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma$358,680
R01 · FY2023 · CA · contact PI
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$593,411
U01 · FY2022 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma$366,000
R01 · FY2022 · CA · contact PI
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$620,991
U01 · FY2021 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma$366,000
R01 · FY2021 · CA · contact PI
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma$366,000
R01 · FY2020 · CA · contact PI
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma$366,000
R01 · FY2019 · CA · contact PI